A unique automation platform for measuring low level radioactivity in metabolite identification studies.
Generation and interpretation of biotransformation data on drugs, i.e. identification of physiologically relevant metabolites, defining metabolic pathways and elucidation of metabolite structures, have become increasingly important to the drug development process. Profiling using (14)C or (3)H radiolabel is defined as the chromatographic separation and quantification of drug-related material in a given biological sample derived from an in vitro, preclinical in vivo or clinical study. Metabolite profiling is a very time intensive activity, particularly for preclinical in vivo or clinical studies which have defined limitations on radiation burden and exposure levels. A clear gap exists for certain studies which do not require specialized high volume automation technologies, yet these studies would still clearly benefit from automation. Use of radiolabeled compounds in preclinical and clinical ADME studies, specifically for metabolite profiling and identification are a very good example. The current lack of automation for measuring low level radioactivity in metabolite profiling requires substantial capacity, personal attention and resources from laboratory scientists. To help address these challenges and improve efficiency, we have innovated, developed and implemented a novel and flexible automation platform that integrates a robotic plate handling platform, HPLC or UPLC system, mass spectrometer and an automated fraction collector.
DMPK/Isotope Laboratories, Novartis Pharma AG, Basel, Switzerland. joel.krauser@novartis.com
Joel
J
Krauser
Markus
M
Walles
Thierry
T
Wolf
Daniel
D
Graf
Piet
P
Swart
D057205:Automation, Laboratory; D001711:Biotransformation; D004353:Drug Evaluation, Preclinical / Q000295:instrumentation / Q000379:methods; D057166:High-Throughput Screening Assays / Q000295:instrumentation / Q000379:methods; D055432:Metabolomics / Q000295:instrumentation* / Q000379:methods*; D011851:Radioactivity